Universal BCMA-CD19 CART not checked
Bioray Laboratories · BRL-302
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Autoimmune Disease
- Main trialPhase 1
- “This is an open label, Multi-center,dose-escalation study in up to 18 participants with refractory NMOSD. This study aims to evaluate the safety and efficacy of universal CAR-T Cells targeting BCMA in the Treatment of refractory NMOSD.”In the company’s words, NCT06633042 on ClinicalTrials.gov
- Other names
- BRL-302
Other drugs for Autoimmune Disease
- RilzabrutinibSanofi · Phase 3
- IMU-838Immunic AG · Phase 3
- TirzepatideEli Lilly · Phase 3
- Descartes-08Cartesian Therapeutics · Phase 3
- HSK39297Haisco Pharmaceutical Group Co., Ltd. · Phase 3
- GefurulimabAlexion Pharmaceuticals, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Unknown | 12 Oct 2025 | The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026